Suparuj Lueangarun1,2, Ratchathorn Panchaprateep1,2. 1. Dr. Lueangarun is with the Division of Dermatology at Chulabhorn International College of Medicine at Thammasat University in Pathumthani, Thailand. 2. Dr. Panchaprateep is with the Division of Dermatology, Faculty of Medicine at Chulalongkorn University, in Bangkok, Thailand.
Abstract
OBJECTIVE: We sought to evaluate the efficacy and safety profile of an herbal extract combination comprising biochanin A, acetyl tetrapeptide-3, and ginseng extracts, and compare this to 3% minoxidil solution for the treatment of andogenetic alopecia (AGA). METHODS: A 24-week, triple-blinded, randomized controlled study was conducted in male and female subjects (N=32) with mild to moderate AGA. All were randomized to receive twice-daily, 1mL applications of the herbal extract combination or 3% minoxidil solution. Clinical efficacy from photographic assessment and adverse reactions were evaluated. RESULTS:There were thirty-two subjects (16 male, mean age 41.3±13.8 years), with AGA onset and duration of 35.5±13.6 and 6.5±5.1 years, respectively. The herbal extract combination demonstrated a comparable efficacy to 3% minoxidil solution. Expert panel photographic assessment observed a response to both treatments in most patients at 24 weeks, with no statistically significant difference in an increase of terminal hair counts (8.3% [P=0.009] and 8.7% [P=0.002] at 24 weeks in the herbal extract combinations and the 3% minoxidil solution groups, respectively). No local adverse reactions from the herbal extract combination were observed, but one subject developed scalp eczema after using the 3% minoxidil solution. CONCLUSION: The non-significant difference in clinical efficacy and safety to 3% minoxidil solution suggests that the herbal extract combination evaluated here could potentially be an alternative treatment with for AGA. Further studies with larger groups and longer follow-up periods are recommended to verify our results.
RCT Entities:
OBJECTIVE: We sought to evaluate the efficacy and safety profile of an herbal extract combination comprising biochanin A, acetyl tetrapeptide-3, and ginseng extracts, and compare this to 3% minoxidil solution for the treatment of andogenetic alopecia (AGA). METHODS: A 24-week, triple-blinded, randomized controlled study was conducted in male and female subjects (N=32) with mild to moderate AGA. All were randomized to receive twice-daily, 1mL applications of the herbal extract combination or 3% minoxidil solution. Clinical efficacy from photographic assessment and adverse reactions were evaluated. RESULTS: There were thirty-two subjects (16 male, mean age 41.3±13.8 years), with AGA onset and duration of 35.5±13.6 and 6.5±5.1 years, respectively. The herbal extract combination demonstrated a comparable efficacy to 3% minoxidil solution. Expert panel photographic assessment observed a response to both treatments in most patients at 24 weeks, with no statistically significant difference in an increase of terminal hair counts (8.3% [P=0.009] and 8.7% [P=0.002] at 24 weeks in the herbal extract combinations and the 3% minoxidil solution groups, respectively). No local adverse reactions from the herbal extract combination were observed, but one subject developed scalp eczema after using the 3% minoxidil solution. CONCLUSION: The non-significant difference in clinical efficacy and safety to 3% minoxidil solution suggests that the herbal extract combination evaluated here could potentially be an alternative treatment with for AGA. Further studies with larger groups and longer follow-up periods are recommended to verify our results.
Authors: S Lueangarun; U Subpayasarn; P Chakavittumrong; T Tempark; W Suthiwartnarueput Journal: Clin Exp Dermatol Date: 2017-05-22 Impact factor: 3.470
Authors: V Kanti; A Messenger; G Dobos; P Reygagne; A Finner; A Blumeyer; M Trakatelli; A Tosti; V Del Marmol; B M Piraccini; A Nast; U Blume-Peytavi Journal: J Eur Acad Dermatol Venereol Date: 2017-11-27 Impact factor: 6.166
Authors: K D Kaufman; E A Olsen; D Whiting; R Savin; R DeVillez; W Bergfeld; V H Price; D Van Neste; J L Roberts; M Hordinsky; J Shapiro; B Binkowitz; G J Gormley Journal: J Am Acad Dermatol Date: 1998-10 Impact factor: 11.527